- Company will exhibit at five major conferences this fall, engaging psychiatrists, pediatricians, child and adolescent psychiatrists, and the broader ADHD community
- Sponsored product theater presentations at US Psych Congress 2026, AAP Experience and NEI Fall Congress will spotlight Tris' proprietary LiquiXR® technology and the Company’s individualized approach to addressing the challenges of suboptimal ADHD care
MONMOUTH JUNCTION, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (“Tris”), a commercial-stage biopharmaceutical company advancing transformative, targeted CNS therapeutics, today previewed its participation in five leading medical conferences this fall focused on ADHD care.
Nearly one in ten U.S. children and roughly one in twenty adults live with ADHD, and diagnosis rates continue to rise.1 Despite the availability of numerous ADHD treatments, many patients continue to experience suboptimal care, underscoring the need for more individualized treatment approaches. As the understanding of ADHD has evolved, there is greater recognition of the variability in patient needs and treatment response, as well as the impact the condition can have on a day-to-day basis. Together, these considerations reinforce the importance of moving beyond a one-size-fits-all approach to ADHD management.
Advances in drug delivery technology have created opportunities to better address the evolving needs of patients. At upcoming conferences, Tris will highlight the Company's proprietary LiquiXR® extended-release technology, reflecting the Company’s continued commitment to educating healthcare professionals on patient-centered approaches to ADHD care across a range of ages and life phases.
For many patients, ADHD symptoms extend well beyond the school or workday, and the level of support patients need can vary throughout the day and from person to person. As understanding of the condition has evolved, it's become clear that this variability is one reason many patients continue to experience suboptimal treatment. Tris' drug delivery technology is designed with that variability in mind, helping support patients through the different parts of their day.
“We're proud to offer one of the largest and most diverse portfolios of ADHD medications available today, because we know there is no one-size-fits-all answer to this condition,” said Manesh Naidu, Chief Commercial Officer of Tris Pharma. “As our understanding of ADHD and the needs of patients continue to evolve, treatment must evolve with it. Patients and families deserve real choice. These conferences give us an opportunity to connect directly with the community, from clinicians to patients to advocates, and share how our product portfolio may help to support improved individualized care.”
Tris’ presence this fall will extend beyond clinical and commercial discussions in ADHD, with Company leaders contributing to broader industry conversations around patient access and commercialization. Beginning in San Diego this September and continuing through early December in Baltimore, Tris’ medical, commercial and market access leaders will engage with healthcare professionals and industry stakeholders across the following conferences:
Hub and Specialty Pharmacy Models West Conference | September 1-2, 2026 | San Diego, CA
- Presentation Title: Optimizing Patient Hubs – Where Access Meets GTN Performance
- Presenters: Lauren Nelson, Head of Market Access & Trade, Tris Pharma and Scott Adams, Director, National Accounts & Patient Access, Tris Pharma
- Date/Time: Wednesday, September 2nd, 2026 from 12:15 PM - 1:00 PM PT
- Location: La Jolla Ballroom AB
US Psych Congress 2026 | September 15–19, 2026 | New Orleans, LA
- Booth: 1519
- Product Theater: DYANAVEL® XR
- Theater Title: Understanding the Impact of Driving with ADHD: The Value of Extended Symptom Control
- Presenter: Andrew Cutler, MD, Chief Medical Officer, Neuroscience Education Institute, Clinical Professor of Psychiatry, SUNY Upstate Medical University; Greg Mattingly, MD, Associate Clinical Professor of Psychiatry, Washington University, President, Midwest Research Group; Jim Potenziano, PhD, Chief Science and Development Officer, Tris Pharma, Inc.
- Date/Time: Wednesday, September 16th at 7:30 AM CT
- Location: Room 208-210
AAP Experience (American Academy of Pediatrics) | October 2–6, 2026 | San Diego, CA
- Booth: 2523
- Product Theater: ONYDA™ XR
- Theater Title: Advancing Pediatric ADHD Management: The Role of the Only Liquid Non-Stimulant Therapy
- Presenter: Dr. Rakesh Jain, MD, MPH
- Date/Time: Sunday, October 5th at 1:15 PM PT
- Location: Theater B
NEI Fall Congress | November 5–8, 2026 | Colorado Springs, CO
- Booth: 500
- Industry Session: ONYDA™ XR
- Theater Title: Advancing Pediatric ADHD Management: The Role of the Only Liquid Non-Stimulant Therapy
- Presenter: Dr. Rakesh Jain, MD, MPH
- Date/Time: Saturday, November 7th at 9:20 AM MT
- Location: Exhibitor Hall, Industry Capsule
International Conference on ADHD (co-hosted by ACO, ADDA & CHADD) | December 3–5, 2026 | Baltimore, MD
- Booth: 218
- Focus Group: ADHD Medication Crashes Message Testing
Healthcare professionals attending any of the five meetings are invited to visit the Tris booths to learn more about the Company's portfolio of ADHD treatment options and its pipeline of investigational CNS therapies.
About Tris Pharma
Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain, addiction and disorders of the central nervous system. Tris markets a portfolio of best-in-class ADHD products and is developing a promising pipeline of differentiated near-term drug candidates.
More information is available at www.trispharma.com and on LinkedIn @TrisPharma.
- Centers for Disease Control and Prevention. (2024, November 18). Data and statistics on ADHD. https://www.cdc.gov/adhd/data/index.html
Contact:
Cheryl Patnick
Tris Pharma
732-823-4940
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
